Sign In
Buy VTGN
$0.231
+0.0019 (+0.83%)
At Close: Jul 20, 2026
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Vistagen T
Contrasting Fulcrum Therapeutics (NASDAQ:FULC) & VistaGen Therapeutics (NASDAQ:VTGN)
01:44am, Wednesday, 07'th Jan 2026
Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) and VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare
Traders Purchase Large Volume of Put Options on VistaGen Therapeutics (NASDAQ:VTGN)
02:07am, Saturday, 27'th Dec 2025
VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) was the target of unusually large options trading activity on Friday. Traders purchased 2,482 put options on the company. This is an increa
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
12:42pm, Wednesday, 17'th Dec 2025
Vistagen Inc. (NASDAQ: VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Appoints Nick Tressler as Chief Financial Officer
08:30am, Monday, 01'st Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026
07:45am, Tuesday, 18'th Nov 2025
Vistagen Therapeutics' intranasal pherine drugs target nose-to-brain circuits. This taps into neuropsychiatric, women's health, and oncology indications. Their lead asset is Fasedienol, which is in Ph
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript
07:01pm, Thursday, 13'th Nov 2025
Vistagen Therapeutics, Inc. ( VTGN ) Q2 2026 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - President, CEO
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
06:55pm, Thursday, 13'th Nov 2025
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.42 per share a year ago.
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
04:30pm, Thursday, 13'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
08:30am, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Participate in Stifel Healthcare Conference 2025
08:30am, Wednesday, 05'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
08:30am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Appoints Paul Edick to its Board of Directors
08:30am, Wednesday, 29'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
